Glenmede Trust Co. NA Buys 441 Shares of Sanofi (NASDAQ:SNY)

Glenmede Trust Co. NA grew its position in Sanofi (NASDAQ:SNY) by 0.7% in the third quarter, according to its most recent filing with the SEC. The fund owned 65,996 shares of the company’s stock after acquiring an additional 441 shares during the period. Glenmede Trust Co. NA’s holdings in Sanofi were worth $3,803,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. POM Investment Strategies LLC bought a new position in Sanofi in the second quarter valued at about $25,000. Northwest Investment Counselors LLC acquired a new stake in Sanofi during the 3rd quarter worth approximately $29,000. Concord Wealth Partners grew its holdings in Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after acquiring an additional 363 shares during the last quarter. Arrow Financial Corp acquired a new position in Sanofi in the 2nd quarter valued at approximately $35,000. Finally, Fortitude Family Office LLC raised its stake in shares of Sanofi by 708.6% during the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock valued at $43,000 after acquiring an additional 659 shares during the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on SNY. StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 7th. Citigroup raised Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Two analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Sanofi presently has an average rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Price Performance

SNY stock opened at $48.49 on Friday. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The company’s fifty day simple moving average is $52.80 and its 200 day simple moving average is $52.13. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97. The firm has a market cap of $123.06 billion, a price-to-earnings ratio of 24.74, a PEG ratio of 1.23 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last announced its earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The company had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. During the same quarter in the prior year, the company earned $2.55 EPS. The firm’s revenue for the quarter was up 12.3% compared to the same quarter last year. On average, analysts expect that Sanofi will post 4.29 earnings per share for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.